These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Involvement of cyclooxygenase-2 in rat models of conjunctivitis. Oka T; Shearer T; Azuma M Curr Eye Res; 2004 Jul; 29(1):27-34. PubMed ID: 15370364 [TBL] [Abstract][Full Text] [Related]
4. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide. Jaworek J; Bonior J; Tomaszewska R; Jachimczak B; Kot M; Bielański W; Pawlik WW; Sendur R; Stachura J; Konturek PC; Konturek SJ J Physiol Pharmacol; 2001 Mar; 52(1):107-26. PubMed ID: 11321505 [TBL] [Abstract][Full Text] [Related]
5. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. Muscará MN; McKnight W; Asfaha S; Wallace JL Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192 [TBL] [Abstract][Full Text] [Related]
6. Effects of novel anti-inflammatory compounds on healing of acetic acid-induced gastric ulcer in rats. Lesch CA; Gilbertsen RB; Song Y; Dyer RD; Schrier D; Kraus ER; Sanchez B; Guglietta A J Pharmacol Exp Ther; 1998 Oct; 287(1):301-6. PubMed ID: 9765350 [TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation. Hsueh SF; Lu CY; Chao CS; Tan PH; Huang YW; Hsieh SW; Hsiao HT; Chung NC; Lin SH; Huang PL; Lyu PC; Yang LC Brain Res Mol Brain Res; 2004 Jun; 125(1-2):113-9. PubMed ID: 15193428 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series. Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960 [TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Michaluart P; Masferrer JL; Carothers AM; Subbaramaiah K; Zweifel BS; Koboldt C; Mestre JR; Grunberger D; Sacks PG; Tanabe T; Dannenberg AJ Cancer Res; 1999 May; 59(10):2347-52. PubMed ID: 10344742 [TBL] [Abstract][Full Text] [Related]
10. Cyclo-oxygenase isozymes in mucosal ulcergenic and functional responses following barrier disruption in rat stomachs. Hirata T; Ukawa H; Yamakuni H; Kato S; Takeuchi K Br J Pharmacol; 1997 Oct; 122(3):447-54. PubMed ID: 9351500 [TBL] [Abstract][Full Text] [Related]
11. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Wallace JL; Chapman K; McKnight W Br J Pharmacol; 1999 Mar; 126(5):1200-4. PubMed ID: 10205009 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818 [TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis. Foitzik T; Hotz HG; Hotz B; Wittig F; Buhr HJ Hepatogastroenterology; 2003; 50(52):1159-62. PubMed ID: 12846004 [TBL] [Abstract][Full Text] [Related]
14. COX-2 inhibitors--is there cause for concern? Seibert K; Lefkowith J; Tripp C; Isakson P; Needleman P Nat Med; 1999 Jun; 5(6):621-2. PubMed ID: 10371498 [No Abstract] [Full Text] [Related]
16. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800 [TBL] [Abstract][Full Text] [Related]
17. Dose-dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase-2 inhibition. Härtel C; von Puttkamer J; Gallner F; Strunk T; Schultz C Scand J Immunol; 2004 Oct; 60(4):412-20. PubMed ID: 15379866 [TBL] [Abstract][Full Text] [Related]
18. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Kurumbail RG; Stevens AM; Gierse JK; McDonald JJ; Stegeman RA; Pak JY; Gildehaus D; Miyashiro JM; Penning TD; Seibert K; Isakson PC; Stallings WC Nature; 1996 Dec 19-26; 384(6610):644-8. PubMed ID: 8967954 [TBL] [Abstract][Full Text] [Related]
19. [New NSAIDS: COX-1, COX-2, what about them?]. Peretz A Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982 [TBL] [Abstract][Full Text] [Related]
20. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Wallace JL; Zamuner SR; McKnight W; Dicay M; Mencarelli A; del Soldato P; Fiorucci S Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G76-81. PubMed ID: 14665439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]